Action ACAD ACADIA PHARMACEUTICALS INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription

Autres langues ACADIA Pharmaceuticals Inc.

Actions

ACAD

US0042251084

Marché Fermé - Nasdaq
Autres places de cotation
 21:59:48 04/06/2024 		Varia. 5j. Varia. 1 janv.
15,44 USD +1,01 % Graphique intraday de ACADIA Pharmaceuticals Inc. +1,55 % -50,70 %
16/05 Transcript : ACADIA Pharmaceuticals Inc. Presents at Bank of America Health Care Conference 2024, May-16-2024 09:20 AM
14/05 Transcript : ACADIA Pharmaceuticals Inc. Presents at The Citizens JMP Life Sciences Conference, May-14-2024 01:30 PM

Autres langues

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Acadia Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(4)
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring, A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
Acadia Pharmaceuticals Announces Launch of Magnolia's Guide to Adventuring: A Groundbreaking Documentary Series Aiming to Raise Disease Awareness and Redefine Perceptions of Rett Syndrome
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million
Acadia Pharmaceuticals to Participate at Upcoming Investor Conferences
ACADIA Pharmaceuticals : Corporate Presentation (1Q24 Earnings)
Earnings Flash (ACAD) ACADIA PHARMACEUTICALS Reports Q1 Revenue $205.8M, vs. Street Est of $208.6M
Acadia: Q1 Earnings Snapshot
Acadia Pharmaceuticals Reports First Quarter 2024 Financial Results and Operating Overview
Acadia Pharmaceuticals Inc. Reiterates Earnings Guidance for the Full Year 2024
ACADIA Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Acadia Pharmaceuticals is Proud to Announce the Winners of the Inaugural Rett Sibling Scholarship
Acadia Pharmaceuticals to Announce First Quarter Financial Results on May 8, 2024
Neuren Pharmaceuticals' Medication Secures Priority Review from Health Canada
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(4)
Acadia Pharmaceuticals' Rett Syndrome Treatment Granted Priority Review by Health Canada
Acadia Pharmaceuticals Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals Inc Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
Acadia Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action ACAD
  4. Actualités ACADIA Pharmaceuticals Inc.
  5. Autres langues
-40% Prolongation exceptionnelle : Nos abonnements vous guident vers les meilleurs investissements de demain.
PROFITEZ-EN MAINTENANT